How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,649 results for

Thyroid Function Summary

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Thyroid transcription factor‐1‐regulated microRNA‐532‐5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells (PubMed)

by repressing expression or inhibiting the function of MKL2 regardless of KRAS mutation status. In summary, our findings show that miR-532-5p is a novel transcriptional target of TTF-1 that plays a tumor suppressive role by targeting KRAS and MKL2 in lung adenocarcinoma.© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. (...) Thyroid transcription factor‐1‐regulated microRNA‐532‐5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells Thyroid transcription factor-1 (TTF-1), also known as NKX2-1, plays a role as a lineage-survival oncogene in lung adenocarcinoma that possesses double-edged sword characteristics. Although evidence from previous studies has steadily accumulated regarding the roles of TTF-1 in transcriptional regulation of protein-coding genes, little is known about

Full Text available with Trip Pro

2017 Cancer science

142. Functional Hypothalamic Amenorrhea

signs or symptoms, including a history of severe or persistent headaches; persistent vomiting that is not self-induced; changes in vision, thirst or urination not attributable to other causes; neurological signs suggesting a central nervous system abnormality; or other clinical signs or test results that suggest pituitary hormone deficiency or excess. Summary of Recommendations 1.1 We suggest that clinicians only make the diagnosis of functional hypothalamic amenorrhea (FHA) after excluding (...) Functional Hypothalamic Amenorrhea '); '); Hypothalamic Amenorrhea Guideline Resources | Endocrine Society Hormone Science to Health / › › › Guidelines and Clinical Practice Section + Hypothalamic Amenorrhea Guideline Resources Full Guideline: JCEM | March 2017 Catherine M. Gordon (chair), Kathryn E. Ackerman, Sarah L. Berga, Jay R. Kaplan, George Mastorakos, Madhusmita Misra, M. Hassan Murad, Nanette F. Santoro, and Michelle P. Warren The 2017 guideline addresses: Diagnosing functional

2017 The Endocrine Society

143. Thyroid Carcinoma

; Francis Worden, MD 12 ; Anamaria Reyna Yeung, MD. 13 Summary of Literature Review Introduction/Background Thyroid cancer is the most common endocrine malignancy in the United States, where the annual incidence is approximately 37,000 and increasing due to the more frequent diagnosis of early well-differentiated thyroid carcinoma (WDTC) [1]. Annually, approximately 1,600 people die from thyroid malignancies [2]. Women represent approximately 75% of newly diagnosed thyroid carcinoma cases. Risk factors (...) , such as systemic therapy options, are being actively investigated. The tyrosine kinase inhibitor axitinib has shown a 30% overall response rate in incurable thyroid cancer of any histology [65], and thalidomide has shown activity in rapidly progressive metastatic thyroid cancer [100]. Patients with metastatic thyroid cancer that is not iodine avid should be encouraged to enroll in clinical trials that further explore novel systemic agents. (See Variant 7 and Variant 8.) Summary ? For WDTC, surgery and often

2013 American College of Radiology

144. Improving Voice Outcomes After Thyroid Surgery

of thyroid surgery remain: complete removal of the abnormal thyroid and any involved lymph nodes, preservation of parathyroid gland function, and maintenance or improvement of voice and swallowing. Reduction in quality of life (QOL) after thyroid surgery is multifactorial and may include need for lifelong medication, thyroid suppression, radioactive scanning/treatment, temporary and permanent hypoparathyroidism, temporary or permanent dysphonia postoperatively, and dysphagia. - Voice disturbance may (...) , there is no evidence-based, multidisciplinary CPG that specifically deals with improving voice outcomes. This guideline is warranted because of known practice variations in the care of patients who undergo thyroid surgery and the large impact resulting voice impairment can have on a patient’s QOL and functional health status. Health Care Burden Thyroid nodules are a major reason for thyroid surgery and are present in 50% of adults in the United States when assessed by ultrasound. In addition, thyroid cancer rates

2013 American Academy of Otolaryngology - Head and Neck Surgery

145. Management of Thyroid Cancer

with thyroid cancer 61 15 Thyroid cancer in childhood 64 16 Pathology reporting, grading and staging of thyroid cancers 16.1 General principles 65 16.2 Pathology report 65 16.3 Pathological staging 65 16.4 Staging protocol 65 16.5 Summary of thyroid cancer types 65 17 Medullary thyroid cancer 17.1 Presentation 69 17.2 Initial investigations of patients with suspected or con? rmed MTC 70 17.3 Treatment 70 17.4 Adjuvant therapies 71 17.5 Pathology 72 17.6 Follow-up for MTC 73 17.7 Investigation of persistent (...) 21.3 Screening 86 21.4 Diagnosis and referral 86 21.5 Summary of treatment of thyroid cancer 87 21.6 Follow-up 88 Appendices 1. Assay methodology 89 2. Recognition of MEN3 (MEN2B) 94 3. Search methodology 95 4. Patient information 97 Patient support groups 97 Websites with useful information for patients 97 Lea? ets for patients 1. The thyroid gland and thyroid cancer – tests and treatment 99 2. Information for patients being investigated for thyroid lumps 102 3. Surgery for thyroid Cancer 104 4

2014 British Association of Endocrine and Thyroid Surgeons

146. Management of Thyroid Dysfunction during Pregnancy and Postpartum

, thyroid tumors, iodine nutrition, postpartum thyroiditis, and screening for thyroid disease. Indications and side effects of therapeutic agents used in treatment are also presented. Summary of Recommendations 1.0. Management of hypothyroidism: maternal and fetal aspects 1.1. We recommend caution in the interpretation of serum free T 4 levels during pregnancy and that each laboratory establish trimester-specific reference ranges for pregnant women if using a free T 4 assay. The nonpregnant total T 4 (...) . If overt hypothyroidism is diagnosed during pregnancy, thyroid function tests should be normalized as rapidly as possible. T 4 dosage should be titrated to rapidly reach and thereafter maintain serum TSH concentrations of less than 2.5 mIU/liter (in an assay using the International Standard) in the first trimester (or 3 mIU/liter in second and third trimesters) or to trimester-specific TSH ranges. Thyroid function tests should be remeasured within 30–40 d and then every 4–6 wk. USPSTF recommendation

Full Text available with Trip Pro

2012 The Endocrine Society

147. Thyroid function normal range defined by the risk of cardiovascular disease and mortality

Thyroid function normal range defined by the risk of cardiovascular disease and mortality Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing (...) to be extracted: other as well as a to meta-analysis of pre-clinical studies are available. Example: A meta‐analysis will be performed for all outcome measures reported in 10 or more articles. For subgroup analysis a minimum of 8 studies per subgroup is required. If meta‐analysis is not possible, data will be reported through a descriptive summary. ">Planned approach Example: number of metastases: standardized mean difference; incidence of metastasis: risk ratio. ">Effect measure The random-effects model

2017 PROSPERO

148. Which Thyroid Antibody Assays Should be Checked in Patients with Thyroid Disease?

Stimulating Immunoglobulins in Graves’ and anti-Thyroglobulin, anti-thyroid peroxidase, and anti-thyroid symporter in all autoimmune thyroid disorders, as well as TSH-blocking antibodies. The TSH-blocking antibodies interfere with the ability of native TSH and TSI to up-regulate the TSH receptor. The net thyroid functional effect is the sum of the trophic and inhibitory factors, anti-enzyme effects, and destructive T-Cell phenomenoa . For example, in Graves’ disease activation of the thyroid stimulating (...) myxedema, or primarily affect several organ systems, like Graves’ disease. The manifestations of ITD are influenced by co-morbidities, past events, environmental factors, and notably local T-lymphocyte phenomena and several immunoglobulins that have unique specificities and impact on thyroid function. TSI binds to and stimulates the TSH receptor to enhance thyroid hormone levels, anti-TPO antibody interferes with the function of the thyroid peroxidase enzyme to reduce thyroxine production, TSH-blocking

2010 Clinical Correlations

149. The association of maternal thyroid function and thyroid autoimmunity with offspring birth-weight

The association of maternal thyroid function and thyroid autoimmunity with offspring birth-weight Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address (...) to be extracted: other as well as a to meta-analysis of pre-clinical studies are available. Example: A meta‐analysis will be performed for all outcome measures reported in 10 or more articles. For subgroup analysis a minimum of 8 studies per subgroup is required. If meta‐analysis is not possible, data will be reported through a descriptive summary. ">Planned approach Example: number of metastases: standardized mean difference; incidence of metastasis: risk ratio. ">Effect measure The random-effects model

2016 PROSPERO

150. Crosstalk between integrin αvβ3 and ERα contributes to thyroid hormone-induced proliferation of ovarian cancer cells (PubMed)

studies indicated that mechanisms involved in T4- and E2-induced nuclear co-localization of phosphorylated ERα and integrin αv are dissimilar. Chromatin immunoprecipitation results showed that T4-induced binding of integrin αv monomer to ERα promoter and this was reduced by ICI. In summary, thyroid hormone stimulates proliferation of ovarian cancer cells via crosstalk between integrin αv and ERα, mimicking functions of E2. (...) Crosstalk between integrin αvβ3 and ERα contributes to thyroid hormone-induced proliferation of ovarian cancer cells Ovarian cancer is the leading cause of death in gynecological diseases. Thyroid hormone promotes proliferation of ovarian cancer cells via cell surface receptor integrin αvβ3 that activates extracellular regulated kinase (ERK1/2). However, the mechanisms are still not fully understood. Thyroxine (T4) at a physiologic total hormone concentration (10-7 M) significantly increased

Full Text available with Trip Pro

2016 Oncotarget

151. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior (PubMed)

with clinicopathological, molecular features and their functional roles. We showed that tOPN and OPNa are overexpressed in classic papillary thyroid carcinoma (cPTC) in relation to adjacent thyroid, adenoma and follicular variant of papillary thyroid carcinoma (fvPTC) tissues. In cPTC, OPNa overexpression is associated with larger tumor size, vascular invasion, extrathyroid extension and BRAFV600E mutation. We found that TC cell lines overexpressing OPNa exhibited increased proliferation, migration, motility (...) Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior Osteopontin (OPN) is a matricellular protein overexpressed in cancer cells and modulates tumorigenesis and metastasis, including in thyroid cancer (TC). The contribution of each OPN splice variant (OPN-SV), named OPNa, OPNb and OPNc, in TC is currently unknown. This study evaluates the expression of total OPN (tOPN) and OPN-SV in TC tissues and cell lines, their correlation

Full Text available with Trip Pro

2016 Oncotarget

152. Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas (PubMed)

histone H3 trimethylation and increased proliferation of thyroid cells. In summary, this study revealed that a hot-spot mutation in EZH1 is the second most frequent genetic alteration in ATAs. The association between EZH1 and TSHR mutations suggests a 2-hit model for the pathogenesis of these tumors, whereby constitutive activation of the cAMP pathway and EZH1 mutations cooperate to induce the hyperproliferation of thyroid cells. (...) Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas Autonomous thyroid adenomas (ATAs) are a frequent cause of hyperthyroidism. Mutations in the genes encoding the TSH receptor (TSHR) or the Gs protein α subunit (GNAS) are found in approximately 70% of ATAs. The involvement of other genes and the pathogenesis of the remaining cases are presently unknown. Here, we performed whole-exome sequencing in 19 ATAs that were paired with normal DNA samples and identified a recurrent

Full Text available with Trip Pro

2016 The Journal of clinical investigation

153. Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self-renewal (PubMed)

by co-binding to the promoter region of BMI1 gene. In summary, our study uncovers a novel function of TH signaling in regulating the CSCs of HCC, and these findings might be useful for developing novel therapies by targeting TH function in HCC cells. (...) Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self-renewal Cancer stem-like cells (CSCs) play a key role in maintaining the aggressiveness of hepatocellular carcinoma (HCC), but the cell-biological regulation of CSCs is unclear. In the study, we report that thyroid hormone (TH) promotes cell self-renewal in HCC cells. TH also increases the percentage of CD90 + HCC cells and promotes drug resistance of HCC cells. By analyzing primary

Full Text available with Trip Pro

2016 Scientific reports

154. Celecoxib for Thyroid Eye Disease

Description Go to Brief Summary: Thyroid eye disease (TED) is an autoimmune disorder in which the immune system attacks orbital tissues, resulting in characteristic changes in eyelid position, globe position in the orbit, extraocular muscle balance, and optic nerve function. TED is a potentially blinding disease, and current treatments largely consist of nonspecific reduction of inflammation using corticosteroids or radiation therapy. Regardless of treatment, once TED progresses from its inflammatory (...) Celecoxib for Thyroid Eye Disease Celecoxib for Thyroid Eye Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Celecoxib for Thyroid Eye Disease The safety and scientific validity of this study

2016 Clinical Trials

155. Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

by (Responsible Party): Suzhou Zelgen Biopharmaceuticals Co.,Ltd Study Details Study Description Go to Brief Summary: Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC). Condition or disease Intervention/treatment Phase Differentiated Thyroid Cancer Drug: Donafenib 200mg Drug: Donafenib 300mg Phase 2 Detailed Description: This phase 2 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety (...) Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Phase

2016 Clinical Trials

156. A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

: February 27, 2019 Sponsor: Eisai Co., Ltd. Information provided by (Responsible Party): Eisai Inc. ( Eisai Co., Ltd. ) Study Details Study Description Go to Brief Summary: The primary purpose of this study is to compare the progression-free survival (PFS) of participants with radioiodine (131 I)-refractory differentiated thyroid cancer (DTC) and radiographic evidence of disease progression within the prior 12 months treated with lenvatinib 24 mg by continuous once daily (QD) oral dosing versus placebo (...) A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2016 Clinical Trials

157. CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

First Posted : December 21, 2018 Last Update Posted : December 21, 2018 Sponsor: National Cancer Institute (NCI) Information provided by (Responsible Party): Naris Nilubol, M.D., National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland. Researchers believe a new drug called CUDC-907 may be able to help (...) for subjects with anaplastic/undifferentiated thyroid cancer who may enroll immediately after discontinuation of previous therapy. Design: Open label, phase II trial to determine response to CUDC-907 treatment. Patients will be given 60 mg of CUDC-907 orally for 5 consecutive days followed by 2 days off (5/2 schedule). One cycle is 21 days. Patients may continue on treatment if there is no disease progression. Initial anatomic and functional imaging will be performed at enrollment and after 2 cycles

2016 Clinical Trials

158. ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy

, Inc. European Commission Information provided by (Responsible Party): Apitope International NV Study Details Study Description Go to Brief Summary: Phase 1 study to assess the safety and biological activity of ATX-GD-59 in patients with Graves Disease not currently treated with anti-thyroid therapy. This will be an open label dose titration involving injections on 10 occasions, each two weeks apart. After dosing is complete there will be a 12 week follow up period. Blood samples will be drawn (...) throughout the study to monitor safety and the body's response to the injections. Thyroid function will be measured throughout the trial to monitor Graves disease progression. Condition or disease Intervention/treatment Phase Graves Disease Biological: ATX-GD-59 Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 12 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment

2016 Clinical Trials

159. The Establish of Specific Reference Ranges for Thyroid Tests in Pregnant Women

, 2016 Last Update Posted : November 22, 2016 Sponsor: Xiaomei Zhang Information provided by (Responsible Party): Xiaomei Zhang, Peking University International Hospital Study Details Study Description Go to Brief Summary: A descriptive analysis involving 300 healthy pregnant women to the establish of trimester-specific reference ranges for thyroid tests in pregnant women. 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. Condition (...) or disease Diseases Pregnancy Thyroid Detailed Description: A descriptive analysis involving 300 healthy pregnant women according NACB to the establish of trimester-specific reference ranges for thyroid tests in pregnant women. According to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. The aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who

2016 Clinical Trials

160. Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules

, 2016 Sponsor: Campus Bio-Medico University Information provided by (Responsible Party): Dr. Silvia Manfrini, Campus Bio-Medico University Study Details Study Description Go to Brief Summary: The purpose of this study is to prospectively compare percutaneous radiofrequency ablation (RFA) versus percutaneous laser ablation (LA) for the treatment of solid thyroid nodules. Condition or disease Intervention/treatment Phase Thyroid Nodule Device: Percutaneous Laser Ablation Device: Percutaneous (...) a reduction ≥50% in the volume of thyroid nodules after 6 months and 1 year follow-up To evaluate whether the features of thyroid nodules as evaluated by thyroid ultrasound, contrast-enhanced ultrasound, power-doppler and core-biopsy influence LA and RFA outcomes To evaluate changes in thyroid function and thyroid autoimmunity after LA and RFA. To evaluate differences between LA and RFA in terms of complications, side effects and tolerability. Patients will be recruited, treated and followed at Santa

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>